Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of novel drugs. The company has obtained marketing authorization for sac-TMT, tagitanlimab, Cetuximab N01, and trastuzumab botidotin, and has filed a New Drug Application for Lunbotinib Fumarate Capsules. Its therapeutic focus includes breast cancer, non-small cell lung cancer, gastrointestinal cancers, gynecological tumors, and genitourinary cancers. The company operates a commercialization team covering marketing, sales, distribution, and medical affairs in China. It pursues a global strategy through out-licensing and collaboration agreements to leverage partners' capabilities for international clinical development and commercialization. The company also explores in-licensing opportunities for new drug candidates and technologies to expand its pipeline. Key subsidiaries include KLUS PHARMA INC. and Sichuan Kelun-Biotech Targeted Biologics Engineering Research Center Co., Ltd.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage kelun-biotech.com
Sector Healthcare IR page —
Tags
oncology, antibody-drug conjugates, targeted therapy, novel drugs, clinical development, biopharmaceuticals, breast cancer, lung cancer, gastrointestinal cancers, out-licensing, sac-TMT, tagitanlimab, Cetuximab N01, trastuzumab botidotin, Lunbotinib Fumarate Capsules, KLUS PHARMA INC., Sichuan Kelun-Biotech Targeted Biologics Engineering Research Center Co. Ltd., Sichuan Kelun Doosan Biotechnology Co. Ltd., Chengdu Kelun Jingchuan Technology Co. Ltd.
Press page —

Metrics

Valuation  
Market cap HK$ 74.61B
Market cap (USD) $ 9.508B
P/E 419.25
PEG —
P/BV 15.27
P/S 30.39
P/OCF 119.23
P/FCF —
Dividend yield —
Turnover / mcap 0.31%
Returns  
ROE -9.3%
ROI -7.8%
ROIC -5.4%
Profit margin -18.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -61.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue 2.058B 1.933B 1.54B 803.933M
Net profit -381.971M -266.766M -574.134M -616.099M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 381.61 125.15 83.34 —
Price performance 12m 2.12 0.51 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Sichuan Kelun-Biotech Biopharm Co Ltd (ticker 6990), listed in Hong Kong.

ETFs Holding Sichuan Kelun-Biotech Biopharm Co Ltd

ETF Weight in ETF Shares Market value As of
MCHS 1.50% 6,700 $ 372.676K Jun 30, 2026
NBCE 0.99% 2,850 $ 180.778K Aug 31, 2026
MINV 0.83% 27,800 $ 1.546M Jun 30, 2026
JSTC 0.02% 894 $ 50.136K Nov 17, 2026
DFAE 0.01% 21,900 $ 1.279M Nov 12, 2026
DFEM 0.01% 15,500 $ 904.948K Nov 12, 2026
DFSE 0.00% 200 $ 11.677K Nov 12, 2026
DFAX 0.00% 1,800 $ 105.091K Nov 12, 2026